Table 2 Comparison of anti-HEV IgG-positive and -negative untreated AIH patients.
AIH (all age groups) | Anti-HEV IgG | Anti-HEV IgG | p value | ||
|---|---|---|---|---|---|
neg | n | pos | n | ||
Age at diagnosis (years) | 26.4 (39.9) | 63 | 56.6 (16.1) | 42 | <0.001 |
Gender (male/female) | 20/43 | Â | 13/29 | Â | 1.000 |
Autoantibodies | |||||
ANA | 8/62 | Â | 7/42 | Â | 0.585 |
SMA | 8/63 | Â | 11/41 | Â | 0.076 |
LKM | 2/62 | Â | 0/41 | Â | 0.516 |
SLA | 2/30 | Â | 0/14 | Â | 1.000 |
pANCA | 11/27 | Â | 3/6 | Â | 1.000 |
Laboratory test | |||||
IgG (times ULN) | 1.4 (0.9) | 62 | 1.5 (0.9) | 41 | 0.407 |
Alanine aminotransferase (times ULN) | 21.4 (22.4) | 61 | 16.6 (25.7) | 40 | 0.317 |
Aspartate aminotransferase (times ULN) | 18.3 (26.2) | 61 | 17.2 (23.3) | 40 | 0.634 |
Alkaline phosphatase (times ULN) | 1.1 (0.5) | 61 | 1.5 (1.1) | 40 | 0.049 |
Bilirubin (times ULN) | 3.2 (15.0) | 61 | 3.3 (9.0) | 39 | 0.992 |
Prothrombin time (%) | 68.0 (32.0) | 60 | 70.5 (36.0) | 40 | 0.620 |
Histology | |||||
mHAI | 9.0 (6.0) | 52 | 9.0 (2.0) | 38 | 0.827 |
Fibrosis (Ishak) | 2.0 (3.0) | 54 | 3.0 (4.0) | 38 | 0.235 |
